Li-Chuan Chan
Impact in
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Immunology top 5%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Immune cells in cancer
Papers in
- Oncology 14
- Cancer Immunotherapy and Biomarkers 8
- PARP inhibition in cancer therapy 5
- Cancer Cells and Metastasis 4
-
- DNA Repair Mechanisms 3
- Glycosylation and Glycoproteins Research 2
- Co-authors
- Mien‐Chie Hung (20 shared papers)Jennifer L. Hsu (16 shared papers)Jong‐Ho Cha (6 shared papers)Chia‐Wei Li (3 shared papers)Jung-Mao Hsu (10 shared papers)Seung-Oe Lim (3 shared papers)Chia-Wei Li (8 shared papers)Heng‐Huan Lee (7 shared papers)
- Journals
- Cancer Research (5 papers)International Journal of Biological Sciences (2 papers)Cancer Letters (1 paper)Journal of Hepatology (1 paper)Molecular Cell (1 paper)
- Partner nations
- TaiwanUnited StatesChina
In The Last Decade
Li-Chuan Chan
26 papers receiving 2.1k citations
Li-Chuan Chan's Hit Papers
Peers
Comparison fields: 5 of 90
- Oncology 1.0k
- Immunology 691
- Cancer Research 341
- Molecular Biology 878
- Pulmonary and Respiratory Medicine 367
Countries citing papers authored by Li-Chuan Chan
This map shows the geographic impact of Li-Chuan Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Li-Chuan Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Li-Chuan Chan more than expected).
Fields of papers citing papers by Li-Chuan Chan
This network shows the impact of papers produced by Li-Chuan Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Li-Chuan Chan. The network helps show where Li-Chuan Chan may publish in the future.
Co-authors
The 25 scholars most cited alongside Li-Chuan Chan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 26 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Mechanisms Controlling PD-L1 Expression in Cancer Hit paper breakdown → | 2019 | 743 |
| 2 | 2018 | 357 | |
| 3 | TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis Hit paper breakdown → | 2021 | 270 |
| 4 | 2020 | 139 | |
| 5 | Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing. | 2018 | 99 |
| 6 | 2019 | 98 | |
| 7 | Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer. | 2018 | 60 |
| 8 | 2011 | 44 | |
| 9 | Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers. | 2015 | 40 |
| 10 | 2022 | 38 | |
| 11 | Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer. | 2019 | 38 |
| 12 | Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer. | 2020 | 36 |
| 13 | 2016 | 34 | |
| 14 | Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells. | 2019 | 29 |
| 15 | 2018 | 24 | |
| 16 | 2020 | 22 | |
| 17 | Inhibition of c-MET upregulates PD-L1 expression in lung adenocarcinoma. | 2020 | 21 |
| 18 | 2023 | 12 | |
| 19 | 2023 | 8 | |
| 20 | 2014 | 8 |
About Li-Chuan Chan
Li-Chuan Chan is a scholar working on Oncology, Molecular Biology, Immunology, Pulmonary and Respiratory Medicine and Biotechnology, having authored 26 papers that have together received 2.1k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (8 papers), PARP inhibition in cancer therapy (5 papers), Immunotherapy and Immune Responses (5 papers), Cancer Cells and Metastasis (4 papers), DNA Repair Mechanisms (3 papers), Immune Cell Function and Interaction (3 papers), Cancer Research and Treatments (3 papers) and Glycosylation and Glycoproteins Research (2 papers). The work is most often cited by research in Oncology (1.0k citations), Immunology (691 citations), Cancer Research (341 citations), Molecular Biology (878 citations) and Pulmonary and Respiratory Medicine (367 citations). Li-Chuan Chan has collaborated with scholars based in Taiwan, United States and China. Frequent co-authors include Mien‐Chie Hung, Jennifer L. Hsu, Jong‐Ho Cha, Chia‐Wei Li, Jung-Mao Hsu, Seung-Oe Lim, Chia-Wei Li, Heng‐Huan Lee, Weiya Xia and Kay‐Hooi Khoo. Their work appears in journals such as Cancer Research, International Journal of Biological Sciences, Cancer Letters, Journal of Hepatology and Molecular Cell.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.